EHA 2026 | Iadademstat and gilteritinib in FLT3-mutated R/R AML: dose expansion portion of the FRIDA trial
In this video, Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, briefly discusses the dose-expansion findings from the Phase I FRIDA trial (NCT05546580), which is evaluating iadademstat plus gilteritinib in patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). Dr Fathi notes that gilteritinib is currently approved for use in this patient population and that the addition of iadademstat, an LSD1 inhibitor, may potentially enhance its activity. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Gilteritinib is approved currently for use in relapsed or refractory FLT3 mutated patients because of a positive phase 3 study comparing it to other standard salvage regimens and showing superiority. This study sought to assess the promise of iadademstat, an LSD1 inhibitor, plus gilteritinib to see whether it can maintain tolerability, but perhaps also enhance activity...
Gilteritinib is approved currently for use in relapsed or refractory FLT3 mutated patients because of a positive phase 3 study comparing it to other standard salvage regimens and showing superiority. This study sought to assess the promise of iadademstat, an LSD1 inhibitor, plus gilteritinib to see whether it can maintain tolerability, but perhaps also enhance activity. And early data emerging from this dose-finding portion of the study have suggested promising activity and good tolerability. So we will see over time whether there is an opportunity to expand on it, perhaps in future clinical trials to improve the current outcomes available with gilteritinib for this patient population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
